Cost-minimization comparison of darunavir plus ritonavir and lopinavir/ritonavir in HIV-1 infected treatment-naïve women of childbearing age

References

• Women and health: today’s evidence, tomorrow’s agenda. Switerzland: World Health Organization, 2009
   Google Scholar
• Kourtis AP, Bansil P, McPheeters M, et al. Hospitalizations of pregnant HIV-infected women in the USA prior to and during the era of HAART, 1994–2003. Aids 2006;20:1823-31
   PubMed Web of Science ®Google Scholar
• Bansil P, Jamieson DJ, Posner SF, et al. Hospitalizations of pregnant HIV-infected women in the United States in the era of highly active antiretroviral therapy (HAART). J Womens Health 2007;16:159-62
   Google Scholar
• Senise JF, Castelo A, Martinez M. Current treatment strategies, complications and considerations for the use of HIV antiretroviral therapy during pregnancy. AIDS Rev 2011;13:198-213
   PubMed Web of Science ®Google Scholar
• Panel on treatment of HIV-infected pregnant women and prevention of perinatal transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf. Accessed September 2, 2012
   Google Scholar
• BHIVA Writing Group. Guidelines for the management of HIV infection in pregnant women 2012. http://www.bhiva.org/documents/Guidelines/Treatment/2012/120430PregnancyGuidelines.pdf. Accessed September 2, 2012
   Google Scholar
• European Aids Clinical Society. EACS Guidelines Version 6.1 - November 2012. http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/EACSGuidelines-v6.1-English-Nov2012.pdf. Accessed December 14, 2012
   Google Scholar
• World Health Organization (WHO). Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendations for a public health approach. http://whqlibdoc.who.int/publications/2010/9789241599818_eng.pdf. Accessed September 2, 2012
   Google Scholar
• Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008;22:1389-97
   PubMed Web of Science ®Google Scholar
• Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. Aids 2009;23:1679-88
   PubMed Web of Science ®Google Scholar
• Möller J, Desai K, Simpson K, et al. Cost of Switching Darunavir + Ritonavir (DRV + RTV) to Lopinavir/Ritonavir (LPV/r) in HIV-1-infected Treatment-naïve Women of Child-bearing Age (WOCBA). Poster presented at HIV-11, Glasgow, Scotland, November 11-12, 2012
   Google Scholar
• Simpson KN, Pei PP, Moller J, et al. Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States. PharmacoEconomics 2013;31:427-44
   PubMed Web of Science ®Google Scholar
• Antiretroviral Pregnancy Registry Steering Committee. The Antiretroviral Pregnancy Registry - Interim report. 2012. http://www.apregistry.com/forms/interim_report.pdf. Accessed September 2, 2012
   Google Scholar
• Karnon J, Stahl J, Brennan A, et al. Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–4. Value Health: J Int Soc Pharmacoecon Outcomes Res 2012;15:821-7
   Google Scholar
• Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profiles. Am Heart J 1991;121:293-8
   PubMed Web of Science ®Google Scholar
• Gathe J, da Silva BA, Cohen DE, et al. A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks. JAIDS 2009;50:474-81
   Google Scholar
• Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008;358:2095-106
   PubMed Web of Science ®Google Scholar
• Henry K, Katzenstein D, Cherng DW, et al. A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/− interleukin 2: results of ACTG A5102. JAIDS 2006;42:140-8
   Google Scholar
• Kelton WD, Sadowski RP, Sadowski DA. Simulation with Arena. New York: McGraw-Hill, 1998
   Google Scholar
• Bardeguez AD, Lindsey JC, Shannon M, et al. Adherence to antiretrovirals among US women during and after pregnancy. JAIDS 2008;48:408-17
   Google Scholar
• Mellins CA, Chu C, Malee K, et al. Adherence to antiretroviral treatment among pregnant and postpartum HIV-infected women. AIDS Care 2008;20:958-68
   PubMed Web of Science ®Google Scholar
• Vaz MJ, Barros SM, Palacios R, et al. HIV-infected pregnant women have greater adherence with antiretroviral drugs than non-pregnant women. Int J STD & AIDS 2007;18:28-32
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics Committee on Pediatric A. HIV testing and prophylaxis to prevent mother-to-child transmission in the United States. Pediatrics 2008;122:1127-34
   PubMedGoogle Scholar
• AnalySource®. AnalySource® Online. http://www.firstdatabank.com/Products/analysource.aspx. Accessed May 20, 2011
   Google Scholar
• Lipscomb MW, Torrance GW. Time preference. In: Gold MR, ed. Cost-effectiveness in health and medicine. New York; Oxford: Oxford University Press, 1996
   Google Scholar
• Huntington SE, Bansi LK, Thorne C, et al. Treatment switches during pregnancy among HIV-positive women on antiretroviral therapy at conception. Aids 2011;25:1647-55
   PubMedGoogle Scholar
• Brogan AJ, Mrus J, Hill A, et al. Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States. HIV Clin Trials 2010;11:133-44
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. 2008. Article ref: 1618
   Google Scholar
• Weinstein MC, O’Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices–Modeling Studies. Value Health: J Int Soc Pharmacoecon Outcomes Res 2003;6:9-17
   Google Scholar
• Mauskopf J, Brogan A, Martin S, et al. Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA. PharmacoEconomics 2010;28(1 Suppl):83-105
   PubMedGoogle Scholar
• Moeremans K, Annemans L, Lothgren M, et al. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK. PharmacoEconomics 2010;28(1 Suppl):107-28
   PubMedGoogle Scholar
• Jaime Caro J, Ozer Stillman I, Danel A, et al. Cost effectiveness of rimonabant use in patients at increased cardiometabolic risk: estimates from a Markov model. J Med Econ 2007;10:239-54
   Google Scholar